RetaLABS Tirzepatide 15mg is the entry-format lyophilised research vial of LY3298176, a dual GLP-1 and GIP receptor agonist developed by Eli Lilly, the first compound in the "twincretin" class
The protein was eluted with buffer containing 20 mM HEPES, pH 7.5, 500 mM NaCl, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 400 mM imidazole and 1 M PF-05190457 and loaded onto an anti-Flag M1 antibody resin after adding 2 mM CaCl 2
For combination therapy (CagriSema), the cagrilintide component is 2.4 mg weekly paired with semaglutide 2.4 mg
At Allpill Biotech, we believe in supporting our Clients with shorter timelines, right from the Product Development phase , through stability profiles and commercialization stage
BPC-175 is studied in relation to mechanisms associated with